Chapter 437 - 262: International Hepatitis B Primary Liver Cancer Treatment Research Group (2)
Chapter 437: Chapter 262: International Hepatitis B Primary Liver Cancer Treatment Research Group (2)
This time, Edwards had thought outside the box. He collaborated with a physics professor from the University of California, Berkeley, to treat Hepatitis B-related hepatocellular carcinoma using the principles of a neutrino collider. The concept was brimming with imagination and technological wonder.
Before the countless cameras of the media, Edwards began his presentation.
Behind Edwards was a large screen displaying a live feed from an operating room. Inside, a machine draped in a silver cloth stood mysteriously, exuding an enigmatic allure.
Before delving into the details of this Neutrino device, Edwards announced the agenda for the day’s conference.
"The first phase of today’s conference will be the global debut and launch of our Neutrino device. In the second phase, we will perform a live surgical demonstration. The third phase will be the partnership signing ceremony and volunteer recruitment!"
As the crowd watched in anticipation, Edwards proceeded to introduce the other core members of his team.
First was Professor Owen from the University of California, Berkeley, a physicist specializing in neutrino collider research.
The second was Morey, Vice President of Ruihui Pharmaceutical Company.
After introducing the team members, Edwards began his explanation of their brand-new core technology.
"Friends, colleagues, and patients, our team’s revolutionary product utilizes a completely new approach and concept—one that none of you could have imagined."
"Neutrino collision technology was originally used to explore our universe and study grand subjects like black holes. However, a chance meeting between Professor Owen and myself led to a wonderful collision of ideas. We turned our focus from the macrocosm of the stars to the microcosm of cellular viruses."
"We discovered a type of neutrino that can penetrate cell membranes without causing any damage and react specifically with the Hepatitis B virus..."
"The specific principles fall into the realm of advanced physics and are quite profound and complex. To put it simply, using a special collider designed by Professor Owen’s team, we built upon the T-neutrino to isolate two additional types of neutrinos that can target the Hepatitis B virus, dismantling its structure and destroying its biological activity."
"I call them: the U-neutrino, the D-neutrino, and the T-neutrino. Of these, the U-neutrino possesses high-energy capabilities to dismantle and destroy..."
"The D-neutrino can eliminate the Hepatitis B virus and its abnormal tissue components. It also instantly induces nitric oxide and nitric oxide synthase, allowing it to simultaneously track and exterminate the virus..."
"The T-neutrino, on the other hand, can interface with T-cells, thereby activating, strengthening, and rebuilding the human immune system..."
"Through the systemic, synchronized action of these three, combined with my own research—the ’targeted decomposition and apoptosis theory’—we can use the collider’s neutrino beam to non-invasively launch a precision strike against the Hepatitis B virus. The only drawback is that, at present, it cannot effectively eradicate deep-seated viruses. Furthermore, it lacks an effective therapy to restore already damaged liver cells."
"Of course, the strengths of our research far outweigh its flaws. After several courses of treatment, we can essentially bring early to mid-stage Hepatitis B-related hepatocellular carcinoma under control. For patients in the mid to late stages, it also provides a palliative effect, improving their quality of life and significantly extending their lifespan!"
As Edwards spoke, the crowd erupted in applause and cheers.
After all, for liver cancer patients, a complete cure was a fantasy. A technology that could significantly improve their condition and bring it under control was already revolutionary!
After explaining the theory, Professor Edwards objectively analyzed the device’s limitations and then presented his second point:
"Besides debuting our Neutrino device, this press conference is also about the future outlook and plans for our world-leading research project."
"Given the current limitations of our Neutrino device, our team is now soliciting proposals from pharmaceutical companies worldwide. We are looking for outstanding antiviral drugs for Hepatitis B-related hepatocellular carcinoma to be used in a combined therapy with our new technology."
"Simultaneously, we are also extending an invitation to teams and experts worldwide in the fields of immunology, as well as liver health and protection, to join us in developing a combined therapy."
"I believe that if we can identify a suitable antiviral drug and combine it with immunotherapy and a restorative therapy for damaged liver cells, this three-pronged approach will allow us to achieve a true cure for Hepatitis B-related hepatocellular carcinoma!"
As they listened to Professor Edwards’s objective analysis and outlook, the prominent figures in attendance were filled with anticipation and admiration.
This was a complete cure for Hepatitis B-related hepatocellular carcinoma. Before this, no research team had ever come so close.
Professor Edwards wasn’t just proposing a theoretical concept, but a clinical application that was already within reach.
Everyone also understood Professor Edwards’s goal: to use this press conference to initiate collaborations with pharmaceutical companies and top medical institutions around the world.
’He plans to introduce the Neutrino device to selected medical institutions, supply them with shortlisted antiviral drugs, and then conduct massive trials around the world to find the single best one.’
’Through this global partnership model, Edwards’s team could first sell their exorbitantly priced equipment, then bundle it with the sale of the initial batch of selected antiviral drugs. After that, they could just sit back and wait for the best clinical results to roll in, allowing them to identify the optimal drug!’